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OBJECTIVES We sought to assess the impact of diabetic retinopathy on long-term outcome among patients
with diabetes and multivessel coronary artery disease (MVD) following coronary artery bypass
graft surgery (CABG).
BACKGROUND For diabetics, CABG is the preferred revascularization strategy. Diabetic retinopathy is a
major microvascular complication of diabetes, and its severity is directly related to total
glycemic exposure.
METHODS We identified 223 consecutive diabetics with MVD whose retinae were evaluated within one
year prior to CABG. The most recent ophthalmologic records up until the time of CABG
were used to evaluate the severity of retinopathy. The median follow-up after CABG was
11.6 years.
RESULTS Diabetic retinopathy was a strong independent predictor of overall mortality (relative risk
[RR], 4.0), and repeat revascularization (RR, 3.0). In separate analyses of diabetics with
retinopathy and without retinopathy, predictors of mortality differed significantly between the
two groups. Among diabetics with retinopathy, the presence of either preoperative renal (RR,
2.5) or ventricular (RR, 2.0) dysfunction had unfavorable effects on mortality, but the survival
curves did not differ significantly according to the presence or absence of internal thoracic
artery (ITA) grafting. In comparison, among diabetics without retinopathy, ITA grafting
(RR, 0.34) had a beneficial effect on mortality, and the survival curves varied somewhat
according to the presence or absence of renal or ventricular dysfunction.
CONCLUSIONS Diabetics with retinopathy had a distinct post-CABG course with a worse long-term
prognosis, as compared with diabetics without retinopathy. Retina evaluation is useful for
prediction of long-term prognosis and management of diabetics who need CABG. (J Am
Coll Cardiol 2002;40:428–36) © 2002 by the American College of Cardiology Foundation
Coronary artery bypass graft surgery (CABG) is the pre-
ferred strategy for coronary revascularization in patients
with diabetes mellitus and multivessel coronary artery dis-
ease (MVD) (1–6). However, even after CABG, the long-
term outcome among diabetics is suboptimal as compared
with among nondiabetics. This unfavorable prognosis is
believed to be related to more rapid progression of athero-
sclerosis within native coronary arteries and grafts, a high
prevalence of myocardial infarction (MI) and persistence or
recurrence of congestive heart failure among diabetics who
have undergone CABG (6–10). In addition, it was reported
that long-term outcome among diabetics after CABG was
associated with severity of diabetes at the time of surgery
(11).
Diabetic retinopathy (DR) is one of the microvascular
complications of diabetes, and its severity is directly related
to the severity and duration of hyperglycemia (12–14).
Recently, epidemiologic studies have reported that patients
with severe DR have a high risk of death from coronary
artery disease (CAD) (15,16). Therefore, diabetics with
retinopathy could constitute some proportion of candidates
for CABG. However, little is known about the prognostic
value of DR among diabetics after CABG. We conducted
this study to assess the impact of DR on the long-term
outcome of CABG among diabetics.
METHODS
Patients. We identified 1,392 consecutive patients who
underwent CABG between April 1977 and May 1993 at
the National Cardiovascular Center, Osaka, Japan. Patients
were eligible for inclusion in our study if: 1) they underwent
first-time CABG for MVD; 2) they were considered to have
diabetes mellitus if medical records review revealed that they
were diagnosed as having type 2 diabetes and had received
medical treatment (hypoglycemic agents or insulin injec-
tion) for diabetes at the time of CABG; and 3) they had
undergone ophthalmologic examination for detection and
treatment of DR within one year prior to CABG at the
Department of Ophthalmology in our center. A total of 269
patients met these criteria. Furthermore, 46 patients were
excluded from the study: 38 because of inadequate data
concerning severity of DR, and 8 because they had
nondiabetes-related retinopathy (4 had retinal branch vein
occlusion, 3 had central retinal vein occlusion and 1 had
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branch retinal artery obstruction). The remaining 223 pa-
tients’ baseline characteristics concerning demographic data,
medical history, coronary risk factors, preoperative and
postoperative angiographic data and operative data were
collected from medical and surgical records. Causes of death
were determined by a review of hospital records and written
questionnaires. All repeat revascularization procedures were
documented for each patient during the entire follow-up
period. The findings reported in this study were docu-
mented for all patients as of March 10, 2001.
Assessment of DR. Ophthalmologic records including
ophthalmologic charts, fundus photography and fluorescein
retinal angiography were reviewed to evaluate patients’
retinae. We used the most recent ophthalmologic records up
until the time of CABG to approximate the stage of DR at
the time of surgery. According to a modification of the
Diabetic Retinopathy Study and the Early Treatment Dia-
betic Retinopathy Study grading scale, the severity in the
worst affected eye was used, and the patients with retinop-
athy were grouped into three categories of retinopathy:
those with mild-to-moderate nonproliferative diabetic ret-
inopathy (NPDR) (only microaneurysms or microaneu-
rysms plus one or more the following: retinal hemorrhages,
soft exudates, hard exudates, intraretinal microvascular ab-
normalities or venous beading); those with severe stage of
NPDR (at least three of the following: extensive retinal
hemorrhages or microaneurysms, soft exudates, intraretinal
microvascular abnormalities and venous beading in two or
more quadrants); those with proliferative diabetic retinop-
athy (PDR) (the presence of new vessels, preretinal or
vitreous hemorrhages, panretinal photocoagulation scars
and a history of vitrectomy) (17,18).
Statistical analysis. We analyzed the data using SPSS for
Windows (version 10.0, SPSS Inc., Tokyo, Japan). Descrip-
tive data for continuous variables are presented as means 
SD. Baseline characteristics of the patient groups were
compared by chi-square test or the Fisher exact test for
categorical variables. The student t test was used for
continuous variables. Overall mortality and repeat revascu-
larization rates were estimated according to Kaplan-Meier
methods and were compared using the log-rank test (19,20).
We used a Cox proportional-hazards model to estimate the
prognostic effect of the variables (21). The potential prog-
nostic variables, which were significant in univariate analy-
sis, were entered into the multivariate model. The following
variables were considered as potential prognostic variables:
older age (65 years), female gender, prior MI, unstable
angina, hypertension, current smoking, treatment with in-
sulin, hyperglycemia (blood fasting glucose 140 mg/dl),
hypercholesterolemia (cholesterol 200 mg/dl), high level
of low-density lipoprotein cholesterol (140 mg/dl), low
level of high-density lipoprotein cholesterol (50 mg/dl),
hypertriglyceridemia (triglyceride 130 mg/dl), preopera-
tive renal dysfunction (serum creatinine1.4 mg/dl), triple-
vessel coronary disease, preoperative left ventricular dys-
function (ejection fraction 50%), internal thoracic artery
(ITA) grafting, the small number of grafts used (no. 3),
complete revascularization and the presence of grafts with
50% luminal stenosis at discharge. Completeness of re-
vascularization was defined as all diseased coronary systems
receiving at least one graft. Two-sided p values of 0.05
were considered indicative of a statistically significant dif-
ference.
RESULTS
Fundus findings. Fundus findings of the 223 diabetics are
shown in Table 1. One hundred forty-four (64.6%) diabet-
ics did not have retinopathy and 79 (35.4%) had DR.
Among 79 diabetics with retinopathy, 39 patients were
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CI  confidence interval
DR  diabetic retinopathy
ITA  internal thoracic artery
MI  myocardial infarction
MVD  multivessel coronary artery disease
NPDR  nonproliferative diabetic retinopathy
PDR  proliferative diabetic retinopathy
RR  relative risk
Table 1. Fundus Findings of Type 2 Diabetic Patients Who
Underwent CABG*
Fundus Findings
No. of
Patients (%)
No retinopathy 144 (64.6)
Mild-to-moderate NPDR 39 (17.5)
Microaneurysms only 10
Microaneurysms, retinal hemorrhages and hard
exudates
17
Microaneurysms, retinal hemorrhages and soft
exudates
12
Severe stage of NPDR 14 (6.3)
Extensive† microaneurysms, retinal hemorrhages
and soft exudates
9
Extensive† microaneurysms, retinal hemorrhages,
soft exudates and intraretinal microvascular
abnormalities
5
PDR 26 (11.7)
Neovascularization‡ 6
Preretinal hemorrhage 2
Vitreous hemorrhage 6
Panretinal photocoagulation scar§ 6
History of vitrectomy 6
Total 223
*Fundus findings were grouped according to severity of diabetic retinopathy prior to
coronary artery bypass graft surgery (CABG). †“Extensive” means involvement of two
or more quadrants of retina. ‡The patients who had both neovascularization and
preretinal or vitreous hemorrhage were counted as having preretinal or vitreous
hemorrhage. §The patients who had preretinal or vitreous hemorrhage after panreti-
nal photocoagulation were counted as having preretinal or vitreous hemorrhage.
Vitrectomy for vitreous hemorrhage or tractional retinal detachment was included,
but vitrectomy for macular edema was not. Patients who had preretinal or vitreous
hemorrhage after vitrectomy were counted as having preretinal or vitreous hemor-
rhage.
NPDR  nonproliferative diabetic retinopathy; PDR  proliferative retinopathy.
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grouped as having mild-to-moderate NPDR, 14 as having
severe NPDR and 26 patients as having PDR.
Baseline characteristics. The baseline characteristics of
the 223 patients according to the presence or absence of
retinopathy are shown in Table 2. As compared with
diabetics without retinopathy, a larger proportion of diabet-
ics with retinopathy were treated with insulin (p  0.001)
and had hypertension (p  0.049).
DR and mortality. The average follow-up from the time of
CABG was 11.6  4.9 years. During the entire follow-up,
of 79 diabetics with retinopathy, 48 (60.8%) died and of 144
diabetics without retinopathy, 27 (18.8%) died. Table 3
shows the causes of death in both groups. Among diabetics
with retinopathy, 32 (40.5%) patients died from cardiac
causes: 13 (16.5%) patients from acute MI, 18 (22.8%) from
congestive heart failure and 1 (1.3%) from ventricular
arrhythmia. Diabetics with retinopathy were more likely to
die from acute MI (p  0.008) and from congestive heart
failure (p  0.001), as compared with diabetics without
retinopathy.
The 12-year overall mortality was 59.5% (95% confidence
interval [CI], 47.9 to 71.2%) for diabetics with retinopathy
and 18.0% (95% CI, 11.5 to 24.5%) for diabetics without
retinopathy. As shown in Figure 1A, overall survival curves
differed significantly according to the presence or absence of
retinopathy (p 0.001). Multivariate analysis demonstrated
Table 2. Baseline Characteristics of Type 2 Diabetic Patients Who Underwent CABG
According to the Presence or Absence of Diabetic Retinopathy*
Characteristic
Diabetics With
Retinopathy
(n  79)
Diabetics Without
Retinopathy
(n  144)
p
Value
Demographic profile
Mean age (yrs) 60.8  8.3 60.1  9.4 0.55
Age 65 yrs, no. (%) 23 (29.1) 40 (27.8) 0.83
Female gender, no. (%) 19 (24.1) 32 (22.2) 0.75
Medical history
Prior myocardial infarction, no. (%) 43 (54.4) 70 (48.6) 0.41
Unstable angina, no. (%) 11 (13.9) 22 (15.3) 0.79
Hypertension, no. (%) 45 (57.0) 62 (43.1) 0.049
Current smoking, no. (%) 39 (49.4) 74 (51.4) 0.77
Treatment with insulin, no. (%) 30 (38.0) 21 (14.6) 0.001
Clinical profile
Mean blood fasting glucose (mg/dl) 122.9  17.9 118.2  21.1 0.097
Blood fasting glucose 140 mg/dl, no. (%) 24 (30.4) 35 (24.3) 0.33
Mean serum total cholesterol (mg/dl) 192.8  41.8 192.5  39.8 0.96
Serum total cholesterol 200 mg/dl, no. (%) 35 (44.3) 58 (40.3) 0.56
Mean serum LDL (mg/dl) 132.8  34.2 134.2  32.1 0.89
Serum LDL 140 mg/dl 30 (38.0) 52 (36.1) 0.78
Mean serum HDL (mg/dl) 61.2  13.2 63.6  11.2 0.78
Serum HDL 50 mg/dl 25 (31.6) 33 (22.9) 0.15
Mean serum triglycerides (mg/dl) 150  59.7 141  56.6 0.29
Serum triglycerides 130 mg/dl, no., (%) 42 (53.2) 71 (49.3) 0.58
Mean serum creatinine (mg/dl) 1.2  0.3 1.1  0.5 0.31
Serum creatinine 1.4 mg/dl, no. (%) 17 (25.3) 22 (15.3) 0.24
Preoperative angiographic profile
Triple-vessel disease, no. (%) 59 (74.5) 99 (68.8) 0.35
Mean ejection fraction (%) 52.4  11.3 53.9  12.8 0.39
Ejection fraction 50%, no. (%) 34 (43.0) 53 (36.8) 0.36
CABG
ITA grafting, no. (%) 36 (45.6) 82 (56.9) 0.10
Mean number of grafts 2.7  0.4 2.6  1.0 0.88
Number of grafts 3, no. (%) 35 (44.3) 78 (54.2) 0.16
Complete revascularization 53 (67.1) 102 (70.1) 0.56
Postoperative angiographic profile
Number of graft stenosis 50%, no., (%) 9 (4.2) 14 (3.7) 0.77
Postoperative medication
ACE inhibitor, no. (%) 32 (40.1) 60 (41.2) 0.87
Beta-blocker, no. (%) 39 (49.3) 68 (47.2) 0.76
Calcium-channel blocker, no. (%) 48 (62.0) 83 (57.6) 0.65
Diuretics, no. (%) 35 (44.3) 61 (42.3) 0.78
Lipid-lowering drugs, no. (%) 25 (31.6) 42 (29.2) 0.70
Nitrates, no. (%) 13 (16.5) 19 (13.2) 0.51
*Plus-minus values are mean  SD.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft surgery; HDL  high-density lipoprotein;
ITA  internal thoracic artery; LDL  low-density lipoprotein.
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that the presence of retinopathy was an independent pre-
dictor of all-causes death (adjusted relative risk [RR], 4.01;
95% CI, 2.41 to 6.68; p  0.001).
DR and repeat revascularization. During the entire
follow-up, 72 patients (32.3%) underwent repeat revascu-
larization: 63 patients (28.3%) underwent additional percu-
taneous coronary intervention and 9 patients (4.0%) under-
went additional CABG. Of 79 diabetics with retinopathy,
36 patients (45.6%) underwent repeat revascularization,
whereas of 144 diabetics without retinopathy 36 (16.1%)
underwent repeat revascularization. Repeat revasculariza-
tion rate at 12 years was 63.7% (95% CI, 49.7 to 77.6%) for
diabetics with retinopathy and 23.4% (95% CI, 15.8 to
31.0%) for diabetics without retinopathy. As shown in
Figure 1B, repeat revascularization rate curves differed
significantly between the two groups (p  0.001). Multi-
variate analysis showed that the presence of retinopathy was
an independent predictor of repeat revascularization (adjust-
ed RR, 3.04; 95% CI, 1.89 to 4.87; p  0.001).
Separate analyses of diabetics with retinopathy and with-
out retinopathy. Diabetics with retinopathy had a distinct
post-CABG course from diabetics without retinopathy.
Therefore, we studied predictors of all-causes death of the
two groups separately. Predictors of overall mortality were
significantly different between the two groups (Table 4). As
shown in Figures 2 and 3, among diabetics with retinopa-
thy, survival curves varied significantly according to the
presence or absence of preoperative renal or left ventricular
dysfunction. The presence of renal dysfunction (adjusted
RR, 2.46; 95% CI, 1.33 to 4.57; p  0.004) and left
ventricular dysfunction (adjusted RR, 2.04; 95% CI, 1.15 to
3.65; p  0.016) were independent predictors of all-causes
death among diabetics with retinopathy. The survival curves
did not differ significantly according to presence or absence
of ITA graft (p  0.13) (Fig. 4). In comparison, among
diabetics without retinopathy the survival curves were sim-
ilar according to the presence or absence of preoperative
renal (Fig. 2) or left ventricular dysfunction (Fig. 3). Among
diabetics without retinopathy, treatment with insulin (ad-
justed RR, 3.01; 95% CI, 1.25 to 7.26; p  0.014) and ITA
grafting (adjusted RR, 0.34; 95% CI, 0.14 to 0.80; p 
0.011) were independent predictors of overall mortality.
Severity of DR and survival. We estimated the degree of
association between severity of retinopathy and long-term
survival. Overall mortality at 12 years was 44.1% (95% CI,
27.4 to 60.8%) for patients with mild-to-moderate NPDR,
64.3% (95% CI, 39.2 to 89.4%) for patients with severe
stage of NPDR and 82.1% (95% CI, 64.8 to 99.4%) for
patients with PDR. We combined severe stage of NPDR
and PDR into a single level of retinopathy because these
two survival curves overlapped each other (survival curves
not shown). As depicted in Figure 5, overall survival curves
were stratified separately according to the severity of reti-
nopathy. Patients with either severe-stage NPDR or PDR
had a higher risk of all-causes mortality than patients with
mild-to-moderate NPDR (RR, 2.10; 95% CI, 1.16 to 3.79;
p  0.012). Furthermore, analysis using diabetics without
retinopathy as the reference group (Table 5) demonstrated
that patients with mild-to-moderate NPDR had a signifi-
cantly higher risk of all-causes death (adjusted RR, 2.41;
95% CI, 1.28 to 4.53; p  0.007) and that patients with
severe stage of NPDR or PDR had a considerably higher
risk of all-causes death (adjusted RR, 5.62; 95% CI, 3.07 to
10.3; p  0.001).
DISCUSSION
It has been demonstrated that diabetics with retinopathy
have a distinct post-CABG course different from diabetics
without retinopathy. Outcome among diabetics with reti-
nopathy was characterized by high mortality and high repeat
revascularization rate. In contrast, long-term survival among
diabetics without retinopathy was excellent particularly
when they underwent ITA grafting. The Bypass Angio-
plasty Revascularization Investigation reported a seven-year
overall survival after CABG among nondiabetics of 86.4%
and the Emory Angioplasty versus Surgery Trial reported
84% at eight years (2,3). In our study, overall survival rate
among diabetics without retinopathy was 87.5% at seven
years and 84.7% at eight years. We cannot directly compare
Table 3. Causes of Death According to the Presence or Absence of Diabetic Retinopathy
During the Entire Follow-Up
Causes
Diabetics With
Retinopathy
(n  79)
Diabetics Without
Retinopathy
(n  144)
p
Value
All causes, no. (%) 48 (60.8) 27 (18.8) 0.001
Cardiac causes, no. (%) 32 (40.5) 10 (6.4) 0.001
Acute myocardial infarction, no. (%) 13 (16.5) 8 (5.6) 0.008
Congestive heart failure, no. (%) 18 (22.8) 2 (1.4) 0.001
Ventricular arrhythmia, no. (%) 1 (1.3) 0 —
Cerebrovascular accidents, no. (%) 5 (6.3) 4 (2.8) 0.20
Malignancy, no. (%) 4 (5.1) 4 (2.8) 0.38
Pneumonia, no. (%) 3 (3.8) 2 (1.4) 0.25
Mediastinitis, no. (%) 3 (3.8) 0 —
Other causes, no. (%)* 1 (1.3) 7 (4.9) 0.95
*Other causes include gastrointestinal disease other than malignancy, aortic disease, diabetic ketoacidosis, suicide and accident.
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our results with previous reports because characteristics of
patients and methods of studies are different. Nevertheless,
in the present study long-term survival of diabetics without
retinopathy seems to be as good as that of nondiabetics in
other studies.
Repeat revascularization could have been due to: 1)
completeness of revascularization; 2) surgical technique; 3)
state of the coronary artery at initial CABG; and 4)
progression of atherosclerosis within native coronary arteries
and grafts following CABG. As for completeness of revas-
cularization, we aimed at complete revascularization for all
patients. However, complete revascularization was not al-
ways technically possible because of poor distal target vessel.
Figure 1. Kaplan-Meier estimates of the overall survival and repeat revascularization rate of type 2 diabetic patients following coronary artery bypass graft
surgery (CABG), according to the presence or absence of diabetic retinopathy (DR). (A) The overall survival curves; (B) subsequent revascularization curves.
DR  diabetic retinopathy. The p values were calculated by the log-rank test. I bars indicate 95% confidence intervals.
Table 4. Multivariate Analysis Among Diabetics With
Retinopathy and Diabetics Without Retinopathy Who
Underwent Coronary Artery Bypass Graft Surgery
Predictors of Overall Mortality
Adjusted Relative
Risk* (95% CI)
p
Value
Diabetics with retinopathy
Serum creatinine 1.4 mg/dl 2.46 (1.33–4.57) 0.004
Preoperative ejection fraction 50% 2.04 (1.15–3.65) 0.016
Diabetics without retinopathy
Treatment with insulin 3.03 (1.25–7.30) 0.014
Internal thoracic artery grafting 0.34 (0.15–0.78) 0.010
*The analysis was adjusted for the prognostic variables, which were significant in
univariate analysis.
CI  confidence interval.
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Figure 2. Kaplan-Meier estimates of the overall survival of type 2 diabetic patients following coronary artery bypass graft surgery (CABG), according to
presence or absence of renal dysfunction (RD) (serum creatinine 1.4 mg/dl). DR  diabetic retinopathy. The p values were calculated by the log-rank
test. I bars indicate 95% confidence intervals.
Figure 3. Kaplan-Meier estimates of the overall survival of type 2 diabetic patients following coronary artery bypass graft surgery (CABG), according to
the presence or absence of left-ventricular dysfunction (VD) (ejection fraction 50%). DR  diabetic retinopathy. The p values were calculated by the
log-rank test. I bars indicate 95% confidence intervals.
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In our study, the absence of complete revascularization was
a predictor of repeat revascularization (RR, 1.65; 95% CI,
1.03 to 2.65; p  0.039) in the univariate analysis, but was
not an independent predictor in the multivariate analysis. As
for surgical technique, in our hospital, cardiac catheteriza-
tion was performed before discharge in all patients so as to
access surgical success. The presence of grafts with luminal
stenosis at discharge was not a predictor of repeat revascu-
Figure 4. Kaplan-Meier estimates of the overall survival of type 2 diabetic patients following coronary artery bypass graft surgery (CABG), according to
the presence or absence of internal thoracic artery (ITA) grafting. DR  diabetic retinopathy. The p values were calculated by the log-rank test. I bars
indicate 95% confidence intervals.
Figure 5. Kaplan-Meier estimates of the overall survival of type 2 diabetic patients following coronary artery bypass graft surgery (CABG), according to
severity of diabetic retinopathy (DR). Overall survival curves were stratified separately according to severity of diabetic retinopathy. The p values were
calculated by the log-rank test. I bars indicate 95% confidence intervals. NPDR  nonproliferative diabetic retinopathy; PDR  proliferative diabetic
retinopathy.
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larization in our study. In addition, the rates of patency of
the grafts did not vary according to the presence or absence
of retinopathy.
Regarding the state of the coronary artery at initial
CABG, our study demonstrated that the presence of triple-
vessel disease was not a predictor of repeat revascularization,
and the presence of DR at CABG was a strong independent
predictor. We believe that diabetics with retinopathy might
have more diffuse coronary disease, compared with diabetics
without retinopathy, although a proportion of patients with
triple-vessel disease did not differ significantly between the
two groups. More diffuse coronary disease among diabetics
with retinopathy might partly contribute to high repeat
revascularization.
As for the progression of atherosclerosis within native
coronary arteries and grafts following CABG, it is generally
accepted that retinopathy does not correlate directly with
macrovascular atherosclerosis within native coronary arteries
and grafts. However, the association of retinopathy with
microvascular dysfunction in turn probably could have a
direct effect on progression of atherosclerosis. One possible
explanation is that DR correlates with duration of disease,
the severity of hyperglycemia and the adequacy of diabetic
control. Diabetics with retinopathy, therefore, have had a
longer period of poor-controlled diabetes and, therefore, are
much more likely to have additional comorbidities and
aggressive disease. In our study, diabetics with retinopathy
were more likely to have hypertension. In addition, DR may
be a marker of diabetic nephropathy. It is the hypertension
and renal disease that are associated with progressive ath-
erosclerosis.
In our study, the overall survival did not differ signifi-
cantly among diabetics with and without ITA grafting in
the presence of DR. This suggests that the effect of ITA
grafting on the long-term survival among diabetics with
retinopathy might be much smaller than among diabetes
without retinopathy. The possible explanation is that among
diabetics with retinopathy and advanced vascular disease,
the benefit of ITA graft becomes small, because target distal
coronary arteries are poor and diseased diffusely. Conversely,
among diabetics without retinopathy, the caliber of the
vessels may be better, which enables the superiority of the
ITA on survival to become manifest.
It is interesting that in the absence of retinopathy there is
really no difference in overall survival among patients with
and without renal dysfunction. The most likely explanation
is that renal dysfunction in diabetics without retinopathy is
not related to diabetic nephropathy. It may be that these are
patients with renal dysfunction due to other factors such as
hypertension. This may be why their prognosis is good.
We have shown that among diabetics with retinopathy
the presence of preoperative left ventricular dysfunction had
an unfavorable effect on survival. This finding might suggest
that CABG conferred small improvement in survival and
ventricular function among patients with these characteris-
tics. In contrast, among diabetics without retinopathy the
survival curves for patients with preoperative ventricular
dysfunction were similar to those of patients without left
ventricular dysfunction, suggesting that CABG conferred a
significant improvement in ventricular function. Nahser et
al. (22) reported that, in diabetics, coronary microvascular
abnormalities may lead to myocardial ischemia in the
absence of epicardial coronary atherosclerosis and contribute
to ventricular dysfunction. We speculate that coronary
microvascular abnormalities among diabetics with retinop-
athy is more profound than that among diabetics without
retinopathy and that this difference may explain the unequal
improvement after CABG between the two groups. Because
CABG “bypasses” only the epicardial stenotic site of coro-
nary artery, CABG alone might not be sufficient to improve
ventricular function among diabetics with retinopathy.
The Diabetes Mellitus, Insulin Glucose Infusion in
Acute Myocardial Infarction study showed that tight glu-
cose control reduced the risk of mortality after MI in
diabetics (23,24). Several studies reported that poor glyce-
mic control was associated with an increased risk of heart
failure among diabetics (25,26). Considering that these
adverse outcomes were more frequent among diabetics with
retinopathy, it would be in this group of patients that a
significant benefit could be conferred from strict glycemic
control with insulin after CABG.
Nowhere is this more “visible” than in the eye, where the
retinal circulation is thought to represent the cerebrovascu-
lar circulation because the retina develops from the forebrain
(27). Furthermore, the retinal changes parallel the duration
and severity of diabetes. We found a significant, graded
association between the severity of retinopathy and overall
mortality after CABG. Therefore, evaluation of retinopathy
may provide a useful means of stratifying risk in the
heterogeneous group of diabetics with coronary artery dis-
ease. Eye examination can be readily performed at the
bedside using the direct ophthalmoscope and, therefore, is
recommended for all diabetics who need coronary revascu-
larization.
Study limitations. The present study has some limitations.
First, our study included diabetics who had undergone eye
examination at any time from one year up until CABG.
Hence, the severity of retinopathy at the time of CABG
may have been underestimated. Second, unrecognized bi-
ases might have led to the selection of patients referred for
Table 5. Association Between Severity of Diabetic Retinopathy
and Overall Mortality After CABG Among Type 2 Diabetic
Patients
Severity of Diabetic
Retinopathy
Adjusted Relative
Risk* (95% CI)
p
Value
No retinopathy† 1.00
Mild-to-moderate NPDR 2.41 (1.28–4.53) 0.007
Severe stage of NPDR or PDR 5.62 (3.07–10.3)  0.001
*The analysis was adjusted for treatment with insulin, high serum creatinine (1.4
mg/dl), low ejection fraction (50%) and internal thoracic artery grafting. †No
retinopathy group served as the reference group.
CI confidence interval; CABG coronary artery bypass graft surgery; NPDR
nonproliferative diabetic retinopathy; PDR  proliferative diabetic retinopathy.
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eye examination. Diabetics who did not have an eye exam-
ination were not included in our study. Such patients might
have severe retinopathy as a result of worse compliance with
glycemic control and of less rigorous ophthalmologic care.
However, the inclusion of consecutive patients minimized
selection bias. Third, our patient population was small, but
this could be compensated by a maximal follow-up of 22
years. Furthermore, with the high mortality among diabet-
ics with retinopathy, power to detect differences in mortality
should be sufficient. Fourth, data on the cause of death were
obtained retrospectively; thus, we were unable to estimate
precisely the impact of DR on cardiac survival.
Conclusions. Diabetic retinopathy has a profound impact
on long-term outcome among diabetics with MVD after
CABG. Evaluation of DR is informative for predicting
long-term outcome after CABG and for developing treat-
ment strategies for diabetics who need CABG.
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